Key statistics
On Thursday, 89Bio Inc (ETNB:NMQ) closed at 8.38, 19.71% above the 52 week low of 7.00 set on Oct 03, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.08 |
---|---|
High | 8.57 |
Low | 7.80 |
Bid | 8.20 |
Offer | 9.10 |
Previous close | 7.98 |
Average volume | 1.23m |
---|---|
Shares outstanding | 117.58m |
Free float | 116.90m |
P/E (TTM) | -- |
Market cap | 985.34m USD |
EPS (TTM) | -2.91 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
- 89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
- 89bio to Participate in the UBS Global Healthcare Conference
- 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
- 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
- 89bio to Participate in Upcoming Investor Conferences
More ▼